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Abstract
Recent developments in light‐controlled therapies (e.g., photodynamic and photother‐
mal therapies) provide promising strategies to prevent and suppress bacterial infections, 
which are a leading cause of morbidity and mortality. Antibacterial photodynamic ther‐
apy (aPDT) has drawn increasing attention from the scientific society for its potential 
to kill multidrug‐resistant pathogenic bacteria and for its low tendency to induce drug 
resistance. In this chapter, we summarize the mechanism of action of aPDT, the pho‐
tosensitizers, as well the current developments in terms of treating Gram‐positive and 
Gram‐negative bacteria. The chapter also describes the recent progress relating to pho‐
tomedicine for preventing bacterial infections and biofilm formation. We focus on the 
laser device used in aPDT and on the light‐treatment parameters that may have a strong 
impact on the results of aPDT experiments. In the last part of this chapter, we survey on 
the various nanoparticles delivering photoactive molecules, and photoactive‐nanopar‐
ticles that can potentially enhance the antimicrobial action of aPDT.
Keywords: bacterial infections, biofilm, antimicrobial photodynamic therapy, laser, 
nanotechnology
1. Introduction
“It is not difficult to make microbes resistant to penicillin in the laboratory by exposing them to con-
centrations not sufficient to kill them, and the same thing has occasionally happened in the body” 
Alexander Fleming, 1945.
In the 1940s, the introduction of the penicillin, discovered in the 1926 by Fleming, opened the 
era of the antibiotics, recognized as one of the greatest advances in the therapeutic medicine. 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
However, the appearance of resistance phenomena came very quickly: by 1944, half of all clin‐
ical Staphylococci spp. isolates failed to respond to the so‐called “miracle‐drug” [1]. The World 
Health Organization (WHO) has recently recognized the multidrug‐resistance (MDR) as one 
of the most important problems facing human health all over the world [2]. The need to over‐
come this rising problem has stimulated research into alternative antimicrobial approaches 
with less potential of developing resistances in microorganisms toward controlling the grow‐
ing incidence of infectious diseases. An innovative light‐based approach to achieve this goal 
is antimicrobial photodynamic therapy (aPDT). The aPDT involves harmless visible light in 
combination with nontoxic and light‐sensitive dye, the so‐called “photosensitizer (PS),” and 
oxygen that can selectively control bacterial infections [3]. Nanotechnology is an emerging 
technology that may change the face of PDT by new photoactive molecules, with numerous 
advantages to gain a successful bacterial infections eradication.
1.1. Photodynamic therapy as antimicrobial strategy: how it works
The photodynamic therapy has gained considerable attention as an emerging treatment 
modality for many forms of neoplastic diseases [4]. However, the PDT was originally discov‐
ered over 100 years ago when Oscar Raab observed that Paramecium spp. protozoans could 
be killed by particular combinations of dyes (acridine orange) and bright light [5]. For many 
years the potential of this finding was forgotten because of the discovery of antibiotics since 
the relentless increase in antibiotic resistance worldwide has spurred a migration of PDT 
research effort to its origin in microbiology. Numerous findings strongly support the hypoth‐
esis that PDT can represent a viable alternative since the mode of action of photodynamic 
sensitizers on microbial cells is markedly different from that typical of most antibiotic drugs 
[6]. aPDT has been successfully applied in vivo and ex vivo tissue or in biological materials for 
blood sterilization, in animal models of localized infections as surface wounds, burns, oral 
sites, abscesses, and in the middle ear. aPDT is being clinically studied for several derma‐
tological infections, such as leishmaniosis and mycobacteria [7]. As mentioned before, PDT 
combines the action of three components: the PS, visible light, and molecular oxygen. The 
absorption of the light by the PS leads to a transition from its initial ground state (PS
0
) to an 
energetically excited state (1PS*) that can relax to the more long‐lived triplet state (3PS*). This 
triplet state can interact with molecular oxygen by two mechanism of reaction, letting the PS 
regain its ground state. Type I photoreactions occurs by an electron and/or proton transfer, 
where the PS interacts directly with the cellular substrate (i.e., lipids, proteins, nucleic acids, 
etc.). The generated radicals react with molecular oxygen, yielding several different oxygen 
intermediates collectively called reactive oxygen species (ROS), such as for instance the super‐
oxide anion (O
2
‐), the hydroxyl radical (OH), and hydrogen peroxide (H
2
O
2
). Alternatively, 
Type II photoreactions proceed by energy (not electron) transfer, while the oxygen is the pri‐
mary acceptor. The interaction of molecular oxygen in its ground triplet state (3O
2
) with 3PS* 
generates a more reactive form of oxygen, i.e., singlet oxygen (1O
2
). This nonradical species is 
highly reactive toward electron‐rich substrates such as aromatic rings, amines, and thioesters 
[8]. The contribution of both Type I and Type II reactions to cell death depends on several 
factors including, among others, the PS itself, the subcellular localization, the substrate, and 
molecular oxygen concentration within the target cells. Although the detailed mechanism of 
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PDT and the concomitant processes are not yet fully understood, it is generally accepted that 
Type I and Type II reactions both produce ROS that cause oxidation of biomolecules (lipids, 
proteins, and nucleic acids) in the cell. For a reason not entirely understood, hyper prolif‐
erating cells selectively uptake PS [9]. This, together with the fact that cell death is spatially 
limited to regions where light of the appropriate wavelength is applied, makes PDT a highly 
selective and useful modality. Because microbial cell possess very fast growth rate, it was 
suggested that PDT could be effective against microbial cells (Figure 1). In most instances, 
aPDT predominantly proceeds via Type II processes. However, by comparing PSs that tend 
to undergo either Type I or Type II mechanism, Huang et al. reported that Gram‐negative 
species are more susceptible to •OH than 1O
2
 [10]. A Type I reaction is therefore favored when 
targeting Gram‐negative species.
1.2. Antimicrobial efficacy of PDT: the photosensitizers
The photosensitizer plays a crucial role in determining the therapeutic outcome. Accumulating 
selectively in diseased tissue and, via generation of cytotoxic species, PS provokes the desired 
biological effect, without causing excessive damage to the host tissue. In general, a PS used for 
antimicrobial PDT should be endowed with the following properties [11]: (i) high triplet‐state 
quantum yields (Φτ ≥ 0.5), triplet‐state with lifetimes long enough (τ microsecond range), 
and sufficiently energetic (≥94 kJ/mol) to produce 1O
2
 (ΦΔ ≥ 0.5); (ii) high‐binding affinity for 
microorganism (positively charged PS for good adherence to negatively charged bacterial cell 
wall) and low‐binding affinity for mammalian cells; (iii) broad spectrum of action, since one 
photosensitizer can act on bacteria, fungi, yeasts, and parasitic protozoa; (iv) minimum dark 
toxicity and negligible cytotoxicity in the absence of light; (v) not yield toxic and mutagenic 
Figure 1. Schematic illustration of photodynamic action.
Can Nanotechnology Shine a New Light on Antimicrobial Photodynamic Therapies?
http://dx.doi.org/10.5772/65974
57
metabolites; (vi) greater retention in target tissue/cells over healthy ones, and (vii) high molar 
extinction coefficients, with high absorbance, particularly in the red and near‐infrared UV‐vis 
spectral regions (600–800 nm range), for a maximum light penetration and minimum light 
scattering within the “therapeutic window.” PSs are usually organic aromatic molecules with 
a high degree of electron delocalization. They contain a central chromophore with auxiliary 
branches (auxochromes) which add further electron delocalization to the PS and thus alter 
the absorption spectra of the PS [12]. As reviewed in [13], different classes of natural and 
synthetic molecules have demonstrated antimicrobial efficacy against a broad spectrum of 
antibiotic‐resistant microorganisms upon illumination. These include porphyrins, chlorins, 
bacteriochlorins, phthalocyanines, as well dyes with different molecular framework such as 
halogenated xanthenes (e.g., Rose Bengal (RB)), perylenequinones (e.g., hypericin), pheno‐
thiazinium salts (e.g., toluidine blue oral (TBO), and methylene blue (MB)), and merocianine 
and cationic fullerenes (e.g., derivatives of C60). PS binding to the bacterial cell and uptake 
are dependent on the microbial species. In general, aPDT has been more effective against 
Gram‐positive and fungal cells than Gram‐negative, especially when neutral or anionic PS 
was used. Gram‐negative bacterial cells are relatively resistant to these compounds [14]. The 
high susceptibility of Gram‐positive bacteria and fungi was explained by their physiology as 
a relatively porous layer of peptidoglycan and lipoteichoic acid, or beta‐glucan and chitin, 
respectively, surrounds their cytoplasmic membrane and both these structures allow non‐
cationic PSs to cross [14, 15]. Gram‐negative bacteria are less prone to take up exogenous 
compounds due to the extra outer membrane and the permeability barrier imparted by lipo‐
polysaccharides [16]. This outer membrane provides also an effective permeability barrier 
and limits the binding and penetration of anionic and lipophilic PS. These critical character‐
istics guided the research efforts toward approaches that would allow PDI of Gram‐negative 
species [14]. A method adopted by numerous groups is to use a PS molecule with an intrinsic 
positive charge [17–19]. An increase of the PDI efficacy has been addressed recently both in 
bacteria using the polycationic biopolymer chitosan [20]. Another method includes the using 
of metal chelators (ethylenediaminetetraacetic acid (EDTA)) or polypeptide polymixin B [21]. 
These agents destabilize the lipopolysaccharides coating by removing the Ca2+ and Mg2+ ions, 
thereby increasing permeability of the Gram‐negative outer membrane and allowing PSs, that 
are normally excluded from the cell, to penetrate to a location where the reactive oxygen spe‐
cies (ROS) generated on illumination that can execute fatal damage [21]. At present, there is 
a consensus that aPDT can be effective to kill all known classes of microorganism, including 
methicillin‐resistant Staphylococcus aureus (MRSA), multidrug‐resistant (MDR) and pandrug‐
resistant (PDR) fungi, protozoa, viruses, etc., whether in vitro or in vivo [13].
1.3. PDT for inactivate biofilm formation
Most important in the chronic infections is the formation of a thick, multilayered biofilm [22]. 
A biofilm is defined as a microbially derived sessile community surrounded by a self‐pro‐
ducing extracellular polymer matrix. The biofilm matrix, a homoglycan composed of β‐1,6‐
linked N‐acetylglucosamine residues, is involved in intercellular adhesion and is referred 
to as polysaccharide intercellular adhesion (PIA) [23]. Biofilm formation includes several 
sequential steps in which planktonic bacteria initially attach to a solid surface, that may be 
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either unmodified or coated with host plasma proteins, followed by cell proliferation, cell‐cell 
interaction, and production of an extracellular polymeric matrix, where bacteria accumulate 
in multilayered clusters (Figure 2).
Biofilms generally do not restrict penetration of antibiotics [24], but they do form a barrier 
to the larger components of the immune system [25]. As a consequence, biofilm‐associated 
 infections can only be resolved by removal of the infected device, determining high‐threat 
care costs. PDT is a possible alternative to inactivate biofilms and may represent a different 
treatment for several recalcitrant infections. There is a wealth of literature that focuses on PDT‐
based antibiofilm strategies against a variety of microbial species [26–28]. On the contrary, 
the effects of PDT on phenotypic biofilm elements (e.g., adhesions and extracellular polysac‐
charide) are poorly investigated [29, 30]. Staphylococci are one of the most important human 
pathogens and a major cause of morbidity and mortality worldwide. In particular, S. epidermi-
dis and S. aureus are emerging as the most important agents of persistent infections, especially 
in implanted medical devices [31, 32]. The use of tri‐meso (N‐methyl‐ pyridyl) and meso (N‐tet‐
radecyl‐pyridyl) porphine (C14) for inactivation of two structurally distinct S. epidermidis bio‐
films grown on Ti6Al4V alloy has been observed and its photosensitizing efficiency with that 
of the parent molecule, tetra‐substituted N‐methylpyridyl‐porphine (C1), was compared [26]. 
In another work, the antimicrobial activity of merocyanine 540, a photosensitizing dye used 
for purging malignant cells from autologous bone marrow grafts, has been evaluated against 
Staphylococcus epidermidis biofilms. Merocyanine 540‐mediated PDT showed a significant inac‐
tivation effect on the viability and structure of biofilms of two Staphylococcus epidermidis strains, 
RP62A and 1457, respectively [27]. Moreover, it was found that erythrosine‐induced PDT was 
also more potent than MB, RB, and TBO against Aggregatibacter actinomycetemcomitans biofilm 
Figure 2. Biofilm development.
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[33–35]. A recent paper described the photokilling propensity of the curcumin (a yellow pig‐
ment derived from the root of the Curcuma longa plant) in S. epidermidis biofilm and suspended 
cells in two in vitro models [28]. Finally, although in many systems the PDT seem promising it 
yields inconsistent results mainly due to the lack of standard reproducible models for assess‐
ing PDT efficacy against biofilms, as well as the lack of robustness of the majority of method‐
ologies used in the majority of  published studies.
2. Laser source and parameters for PDT in microbial infections
Given the always present variability in biological experiments, and the need to allow for 
experimental results comparison, we give in this section a guide that will help the reader to 
understand the properties of laser sources, the physical phenomena occurring in the treated 
samples, the parameters to be defined in order to set a reproducible experiment, and also the 
technical aspects regarding the instruments required for a proper optical beam characteriza‐
tion. In order to understand why lasers are generally used to carry out PDT experiments, it is 
helpful to recall the main differences between the radiation emitted by a lamp and that emit‐
ted by a laser. As everybody knows the most “visible” differences between lamps and lasers 
are the directionality of laser light, and the fact that it is generally “colored” and not white. 
The directionality aspect of laser light is of fundamental importance when a selective illumi‐
nation is required, as it allows illuminating certain portions of the sample/tissue, or a specific 
position of a multiwell plate without irradiating the neighboring area. The laser light direc‐
tionality thus enables comparing the biological effect in treated versus untreated areas on the 
same substrate and makes it possible to exploit relatively simple components (lenses and mir‐
rors) in order to control the optical beam properties, as direction and diameter. In particular, 
the possibility to properly control the beam properties is of great importance in some recently 
investigated techniques, as two‐photons PDT [36] where the PDT is activated only in the focal 
region of the optical beam, thus making possible to induce PDT in “deep regions” without 
affecting all the biological material irradiated. From the physical point of view, the fact that 
the laser light is characterized by a specific “color” means that the emitted electromagnetic 
radiation has a very specific wavelength. On the contrary, the “white light” emitted by a lamp 
is given by the simultaneous presence of radiations with different wavelengths, covering the 
whole spectrum of visible light and generally comprising even radiation in the ultraviolet 
(UV) and infrared (IR) range. Even if it is always possible to select a well‐defined wavelength 
(i.e., a “color”) from a white light source by inserting an optical filter along the light path, the 
obtained beam characteristics are still quite different, mainly because of two reasons: light 
“line‐width” and the achievable “power.” It is worth noticing that the exact line‐width value 
depends on many parameters and in certain cases, it can be reduced to reach values in the 
kHz range, but an in‐depth discussion of the parameters affecting laser line‐width is beyond 
the aim of this section [37]. The origin of these laser beams characteristics is strictly related 
to the structure of a laser source, which is thus briefly described in the following. The word 
“laser” is the acronym of light amplification by stimulated emission of radiation [38], thus 
immediately suggesting that what we call “laser light” is the result of an amplification mecha‐
nism, and that a “light amplifier” should be used in order to produce laser light. The laser 
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source is composed by two main components: the “active medium,” which is the element 
amplifying the light beam thanks to the stimulated emission process [39], and the “cavity,” 
used to provide the feedback required to transform the amplifier in an oscillator. The “active 
medium” obviously requires some form of power supply, as otherwise no amplification could 
occur because of the general energy conservation principle, and the way that power is trans‐
mitted to the active medium is generally called “pumping method” (or scheme) (Figure 3). As 
the material used as active medium determines the frequency of the emitted laser light, laser 
sources are generally identified by describing the active medium; this is the reason why lasers 
are generally classified as either “solid state,” “gas,” “fiber,” or “semiconductor” lasers. The 
role of the cavity is that of creating the “selection” of the light components to be emitted. This 
selection is both a “frequency (or wavelength) selection,” and a “direction selection”: only 
those wavelengths that are exact dividers of the cavity length can be in fact emitted by a laser 
source (the so‐called “cavity autofrequencies”) and only those rays propagating sufficiently 
aligned to the cavity axis, so that they can be reflected several times before transmission, are 
actually selected by the cavity feedback.
The most suitable laser for PDT experiments and applications is probably that of the so‐called 
semiconductor lasers. The first demonstration of the possibility to produce laser light from 
a semiconductor dates back to 1962 [40, 41], just two years after the first ever demonstration 
of a laser source. The main advantage of semiconductor lasers with respect to the other laser 
types (gas, solid, and fiber lasers) is the possibility to electrically pump the active medium, 
without requiring the use of additional light sources, thus significantly increasing the sys‐
tem efficiency. Because of the combination of high efficiency (and thus small power supply 
requirements) and small size (generally <1 mm3), semiconductor lasers are the ideal choice to 
realize portable, and maybe even battery‐operated, hand‐held laser devices. Regarding the 
optical wavelengths that can be emitted by semiconductor lasers, these are related to the so‐
called “energy‐gap” of the semiconductor, which in turns depends on the semiconductor lat‐
tice composition. As an example, considering an Ga
x
Al
1‐x
As semiconductor it is thus possible 
in principle to tune the emission wavelength between 570 and 850 nm by changing the value 
Figure 3. Example of the generation of laser beam into a cavity.
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of the x parameter (while keeping it between 0 and 1) in the composition formula. From the 
practical point of view, commercial products, because of fabrication issues, cover not all the 
theoretically available wavelengths. The “unpleasant side” of semiconductor lasers is related 
to the properties of the optical beam. The small cross‐section of the active medium makes the 
optical beam to be extremely small directly at the laser output, and in general with an ellipti‐
cal shape. The very small size induces the beam diffraction phenomenon, making the beam 
profile broader and broader during propagation.
2.1. Laser wavelengths and irradiation system setup
A fundamental point in the preparation of the PDT experiments is the wavelength of the 
laser used in the system. In particular, it is useful to recall that the absorption spectrum 
of the photosensitizer (PS) is not the only parameter to be considered, but other elements, 
such as the light absorption due to the culture medium or the depth at which the target cells 
are located (when performing in vivo experiments), may impose significant constraints to 
the choice of the wavelength to be used, and hence on the laser choice. As a first step for 
the wavelength determination, it is necessary to measure the absorption spectrum of the 
PS, paying attention to the fact that slight modifications of the PS absorption curve may 
be observed when changing the medium where the PS is dispersed. After having deter‐
mined the PS absorption peak, it is important to check if the corresponding wavelength may 
induce local medium/sample heating, generally checking if the absorption peak lies within 
the “biological window” (a wavelength range roughly going from 650 to 1300 nm) [42]. If 
the PS absorption peaks is within the biological window it is possible to assume a good pen‐
etration (>1 cm) of the light beam in a standard sample; conversely, if the absorption peak 
is out of the window a more detailed analysis is required, in order to understand which are 
the components that could cause light absorption, and the consequences of their presence 
in terms of heat production, light scattering, and penetration. When the desired wavelength 
has been selected, it is then necessary to find a suitable laser source. Limiting the discussion 
to semiconductor lasers, the most used in PDT, it is interesting to notice that even if several 
different sources are available inside the “biological window” they do not uniformly cover 
the required biological range and some “dark ranges” are present. This implies that even if 
a small (generally <1%) tuning of the emission wavelength is possible thanks to tempera‐
ture tuning of the semiconductor chip, some “dark” wavelength range still exist, and thus 
custom solutions may be required. Additionally, from what has been reported it is probably 
now obvious that when multi‐PS studies are considered it would be ideally required to have 
different laser sources, whose emission wavelengths correspond to the PS absorption peaks. 
As an alternative, if the absorption spectra of the tested PS all have a common “absorption 
region,” it is possible to use a single laser, by fine‐tuning the optical power to balance for 
the different absorption coefficient. As an additional possibility, if the laser system offers 
this possibility, the emission wavelength can be slightly changed (e.g., by controlling the 
source temperature in semiconductors lasers) to match the PS absorption peak. In order 
to realize a suitable irradiation system for PDT experiments, it is important to notice that 
the availability of the laser source is required but definitely not sufficient. We thus give 
a short list and description of the elements required for a proper setup preparation. The 
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 semiconductors lasers are generally sold as a “component,” implying the use of a suitable 
mounting and right drivers for controlling both the current injected to the semiconductor 
(to tune the emitted‐beam power) and the temperature. It is thus important, when planning 
a PDT experiment to: (i) acquire the right drivers, which can be relatively expensive, even if 
they can be often reused in future experiments simply changing the semiconductor sources; 
(ii) consider the set of lenses/mirrors to control and steer the optical beam, and the corre‐
sponding mechanical mounts, allowing to keep the optical elements in a stable and well‐
defined position. Moreover, for an accurate characterization three elements are required: (i) 
an optical spectrum analyzer, for guarantee the stability of the wavelength emitted by the 
laser source over time (as it may drift in case of nonaccurate thermal control); (ii) a power 
meter to verify that the laser operating conditions remain stable even after months of usage 
[43], and (iii) a properly calibrated camera to acquire the spatial intensity distribution and to 
analyze the obtained images so as to guarantee that the beam uniformity requirements are 
met on the whole surface.
2.2. The “light‐treatment” plan
Finally, it is helpful to highlight which are the light‐treatment parameters that may have a 
strong impact on the results of PDT experiments. While the idea of “light‐dose” (measured 
in J/cm2) is generally accepted and used in the scientific literature in this field, careful analy‐
sis must be performed before comparing results of experiments using the same light‐dose 
on identical samples. A first parameter is the beam wavelength: even very small beam wave‐
length variations (e.g., <1 nm) can have a strong impact on the ability of the beam to excite 
the PS, especially if the considered beam wavelength is close to the absorption edge and 
not exactly in the middle of the absorption spectrum. A second parameter, which is often 
overlooked, is the beam intensity (i.e., the ratio of the optical power over the irradiated sur‐
face) impinging on the sample and measured in W/cm2. As an example, a 1 W laser beam 
and a 10 MW beam impinging on the same surface may be used to apply the same “light‐
dose” by simply scaling (by a factor of 100) the irradiation times between the two beams. 
Nevertheless, in the first case the beam intensity will be two orders of magnitude higher, 
leading to a significantly different interaction between the light beam and the biological 
sample. As a consequence, this means that in order to properly define a suitable light‐irra‐
diation plan, it is not sufficient to keep the laser intensity at a fixed level and to investigate 
the role of different doses, but it is instead necessary to vary both the light intensity and the 
exposure‐time parameter, so as to create a “data‐grid” allowing to optimize both parameters 
(Figure 4).
Additionally, the role played by localized thermal heating, due to absorption, may become 
relevant in PDT experiments, with two consequences: it is necessary to properly evaluate 
the produced temperature increase, and if the heating is nonnegligible, it is important to 
model the thermal situation of the experiment. Furthermore, when very high intensities 
are considered (for example, by using pulsed lasers), several other aspects must be con‐
sidered, such as the possibility to induce photoablation and two‐photons light absorption 
(i.e., the light beam is absorbed even if the medium absorption at the beam wavelength is 
very low).
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3. Nanotechnology shines a new light in antimicrobial PDT
Although the efficacy of PDT has been recognized, inefficient PS uptake by bacteria could 
result in insufficient therapeutic index. It is now clear that a nanotechnology‐driven approach 
using nanoparticles can overcome this problem, increasing the efficiency and efficacy of 
aPDT. Several types of nanoparticle (NP) systems have been studied to potentiate antimicro‐
bial PDT with the aim of improving photosensitizer solubility, photochemistry, photophysics, 
and targeting [44]. There are two different ways to combine nanoparticles and PDT for anti‐
microbial applications: (i) the noncovalent encapsulation or incorporation of PS in nanosys‐
tems, and (ii) the covalent binding of the PS to the surfaces of the nanoparticles. Furthermore, 
Figure 4. Log‐log chart describing the interactions produced as a function of the beam intensity and of the irradiation time.
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the nanomaterial itself can take part in the optics, physics, and chemistry of the photodynamic 
process, capable of photodynamically inactivate microorganisms. As reviewed in [44], com‐
pared to free the encapsulation of PS in nanoparticles show several advantages: (i) transport 
a larger concentrations of PS for the production of lethal reactive oxygen species; (ii) enhance 
the solubility of nonsoluble water PS; (iii) a controlled release of PS, concentrating the PS in 
inflammatory and infectious locations by virtue of their enhanced permeability and preserva‐
tion; (iv) increase the targeting to specific cells and tissues and reduced ability of the target cell 
to pump out the PS, hence reducing the possibility of multidrug resistance; (v) stopping the 
PS from dimerizing and trimerizing as it occurs in the free state, forms that are ineffective; and 
(vi) a selectivity of treatment achieved through either passive targeting or by active targeting 
(charging of the nanoparticle surface). We will give some examples of nanostructures that 
have been investigated as PS‐delivery systems. As the main application of aPDT is likely to be 
in the medical (wound and surfaces sterilization) and environmental fields (food industry 
and water purification), particular interest has been placed on biocompatible and biodegrad‐
ables nanomatrix, such as polymeric nanoparticles [45], micelles [46], and liposomes [47]. The 
use of biodegradable polymeric nanoparticles as PS‐delivery nanoparticles has been recently 
reported. Polylacticglycolic acid (PLGA), polyacrylamide (PAA), and calcium phosphate have 
been used as PS polymeric carriers. For example, see in [48], it has been demonstrated how 
preparation of poly(lactic‐co‐glycolic acid) nanoparticles loaded with the PS methylene blue 
(MB) is effectively not only against biofilm formation, but is also able to kill cells already 
formed in the biofilm. Moreover, calcium phosphate nanoparticles can be used as efficient 
carriers for MB and porphyrin, against S. aureus and Pseudomonas aeruginosa bacteria [45]. 
Hypericin (a natural potent photosensitizer) can be embedded in amphiphilic block copoly‐
mers to form Hypericin‐NPs, that when light activated demonstrated better inhibition of bio‐
film cells compared with planktonic cells [49]. Therefore, the encapsulation of PS in 
nanoparticles opens a new door for the treatment of infections with minimal side effects. 
Recently, Chlorine 6 (Ce6), a potent PS used in cancer therapy, has been encapsulated in 
charge‐conversion polymeric nanoparticles (NPs) for efficiently targeting and killing patho‐
genic bacteria in a weak acidic urinary tract infection environment [50]. Additionally, natu‐
rally occurring polymers, such as chitosan and cellulose can be used as novel starting material 
for the preparation of nontoxic nanoparticles with photobactericidal action [51]. Liposomes 
nanoparticles are also employed as antimicrobial drug delivery vehicles because their lipid 
bilayer structure imitates the cell membrane and can readily fuse with infectious microbes. 
The hydrophobic center of these bilayers can accommodate hydrophobic drugs or PS, while 
the hydrophilic central region or core can accommodate water‐soluble drugs or PS [52]. 
Liposomes exert their antimicrobial activity through different mechanisms: (i) the fusion with 
the cell membrane and the release of PS into the cytosol; (ii) the increase in solubility and 
stability of PS; or (iii) the engulfment of these liposomes in phagocytic cells and their disinte‐
gration inside the endosomes or lysosomes, thereby releasing the active PS into the cell [51]. 
However, the properties of liposome influence mostly the action of liposomes to alter PS dis‐
tribution. For example, their zeta potential is a determinant parameter influencing their 
aggregation. It has been showed that values close to zero induce their aggregation, thereby 
reducing the antimicrobial activity [53], on the contrary if these values are too high (>40 Mv), 
dark toxicity is present [54], whereas negative potentials result in repulsion between bacterial 
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cells and nanoparticles. An important parameter is the surface charge of liposomes [55]. In 
particular, cationic liposomes are more effective than neutral or anionic ones in aPDT because 
of the establishment of electrostatic attraction with the negatively charged cell wall, which 
facilitate the interaction of liposome to microbial wall, and then the delivery of the PS into the 
microbial cells. Cationic liposomes for aPDT have been formed from different lipids including 
the lipid N‐[1‐(2, 3‐dioleoyloxy)propyl]‐N,N,N‐trimethylammonium methylsulfate (DOTAP), 
the dl‐a‐dipalmitoyl‐phosphatidyl‐choline (DPPC), and the l‐a‐dimyristoyl‐phosphatidyl‐
choline (DMPC) [55, 56]. As mentioned before, nanoparticles can also improve the efficacy of 
aPDT either increasing the 1O
2
 yield of the PS and by covalently binding the PS to the surface 
of the nanoparticles. In this design, the PS appears to remain on the surface of the NP, but the 
NP itself still dictates pharmacokinetics [57]. Theoretically, the singlet oxygen would be more 
available when generated from the surface than from diffusing with a NP [58]. Rose Bengal is 
one of the most frequently used PS due to its availability, high water solubility, high singlet 
oxygen quantum yield, and low rate of photodegradation, and has been linked to polystyrene 
for inactivating E. coli and to silica nanoparticles to inactivate Gram‐positive bacteria, includ‐
ing methicillin‐resistant Staphylococcus aureus [59]. In another study, S. aureus has been inacti‐
vated with porphyrin bound to carbon nanotubes [60], while the toluidine blue oral (TBO) has 
been bound to the surface of Au nanoparticles and have been shown to be effective against S. 
epidermidis [61]. What promises to be even more exciting, are those applications where the 
nanomaterial can acts as PS. The carbon nanomaterials (fullerenes, nanotubes, and graphene) 
are being discovered to be photoactive in their own right, exhibiting intriguing photo‐induced 
electron transfer properties. Such molecules are particularly attractive due to their long wave‐
length of absorption, the high quantum yield, and lack of acute toxicity, except in rare cases, 
in the absence of light. Fullerenes (C60) are the third type of carbon structure; they consist of 
60 carbon atoms arranged in a spherical structure that can absorb light and be active PS [62], 
they generate different ROS according to the solvent, and in polar solvents they produce 
superoxide and hydroxyl radicals, while in nonpolar solvents they predominantly generate 
singlet oxygen. As shown from recent studies, their functionalization (with multiple attached 
cationic groups) make them more soluble in water or other biological fluids and more active 
for targeting and killing different bacterial species [63]. Titanium oxide (TiO
2
) has been more 
widely studied as a PS among metal oxide nanoparticles in a process termed “photocataly‐
sis,” which has been proposed as an antimicrobial strategy for disinfection of surfaces, air, 
and water [64, 65]. Photocatalysis is the acceleration of a light‐mediated reaction in the pres‐
ence of a catalyst (usually an inorganic semiconductor) [64]. The advantage of photocatalysis 
is having sunlight or UV‐radiation to trigger the disinfection process using a catalyst (TiO
2
) 
[66, 67]. The process has been shown to be capable of killing a wide range of organisms includ‐
ing Gram‐negative and Gram‐positive bacteria, endospores, fungi, algae, protozoa, and 
viruses, and has also been shown to be capable of inactivating prions [68]. However, the use 
of UV‐region is also the main obstacle to the use of TiO
2
 nanoparticles for medical applica‐
tions. As a consequence, the research efforts has been in shifting the absorbance spectrum of 
TiO
2
 toward the visible region through doping the titanium surface with other elements, such 
as ytterbium (Yb3+), erbium (Er3+) [69], and argent [70] ions. Furthermore, the coating with 
argent and copper, both antimicrobial agents, can enhance the killing activity of TiO
2
 [71, 72]. 
Metal nanoparticles usually are of very small size (i.e., ranging from one to a few nanometers) 
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and are characterized by a high monodispersity. Most applications of metallic NPs stem from 
the principle of their surface functionalization (unprotected metal NPS are highly sensitive to 
air), which allows loading them with large PS doses. Typical metals employed for this pur‐
pose include gold, silver, platinum, and palladium. Gold (Au) is not intrinsically antibacterial 
but gold nanoparticles possess two or more localized surface plasmon resonances (LSPR) that 
undergo thermal relaxation upon irradiation. This property has been employed to potentiate 
the photodynamic inactivation. Using different methods of preparation, Au‐based nanomate‐
rials such as Au nanospheres, Au nanostars, and Au nanorods can be obtained to inactive 
bacteria by a photothermic process [73]. Thus, Au‐nanoparticles can be conjugated with spe‐
cific antibody [74], PSs [75], and antibiotics [76], or have intrinsic antibacterial activity [77, 78]. 
Furthermore, it has been observed that the coating of glass materials with gold nanoparticles 
proved to be very efficient in photothermal biofilm laser treatment against S. aureus biofilms, 
suggesting the possibility of fabricating medical devices with the same coating: once internal‐
ized, they would not need to be removed if a biofilm is formed on their surface but may be 
treated in situ, i.e., through tissues, avoiding surgical removal (Figure 5) [79].
Finally, recent studies have proposed that rare earth mineral nanoparticles (the so‐called up‐
conversion nanoparticles, consisting of sodium yttrium fluoride (NaYF
4
) codoped with ytter‐
bium and erbium ions [80]) can be used to transduce near‐infrared light into required short 
wavelength light for activate powerful photosensitizers and for a better penetration of PS into 
the tissues.
Figure 5. Monolayers of gold nanostars (GNS) grafted on mercaptopropyltrimethoxysilane‐coated glass slides for aPDT 
application.
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4. Conclusion
This chapter provides a state‐of‐the‐art analysis about the use of phototherapy and nanotech‐
nology to resist or counteract implant infections, together with a glimpse of the future pos‐
sible applications and main trends occurring in the field. Progress in the field will correlate 
with a better understanding of photophysics, chemistry, materials science, biology, and clini‐
cal practice, which will allow a rational design of the whole investigation protocol, ranging 
from optimized formulations to the development of suitable tools for photosensitizers and 
light beams delivery. Nanotechnology is one of the most rapidly growing fields of trans‐
lational medicine, and its potential impact on photodynamic therapies is extremely wide. 
The convergence of phototherapy and nanotechnology may provide new therapeutic modali‐
ties (e.g., new nanophotosensitizer formulations) that are easy to apply throughout the body 
in a targeted manner. In conclusion, exploring the current and possible future interactions 
between nanotechnology and PDT will offer new outlooks on their bactericidal potentiality.
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